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‘narcoleptic symptom pentad’ includes excessive day-
time sleepiness (EDS), cataplexy, sleep paralysis, hypna-
gogic hallucinations and sleep fragmentation. NC is sug-
gested to be an immune-mediated disorder affecting ge-
netically predisposed individuals coupled with exposure 
to environmental factors. The genetic background is 
strongly associated with the HLA-DQB1 * 06: 02 genotype 
 [2] . Among environmental factors, bacterial (streptococ-
cus pyogenes) or viral (influenza A H1N1) infections and 
H1N1 vaccination have been correlated with the onset of 
NC  [3–5] . Ultimately, the suggested autoimmune pro-
cess degrades hypocretin-producing neurons in the lat-
eral hypothalamus as the main cause of the NC symp-
toms  [6] .
 Since 2010, several epidemiological observations and 
studies have pointed to an increased occurrence and risk 
(3–15 fold) of narcolepsy following H1N1 flu vaccination 
in autumn 2009  [4, 5, 7–10] , as well as after H1N1 disease 
 [11] . The provoking effect of H1N1 vaccination was pri-
marily and mainly observed in children, adolescents and 
young adults  [4, 7–10] .
 Different causes for the specific role of Pandemrix ® 
being the pivotal trigger for post H1N1 NC are discussed 
(e.g. AS03 adjuvant). Recently, a higher amount of poly-
meric H1N1 virus nucleoprotein probably due to differ-
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 Abstract 
 Narcolepsy-cataplexy is a sleep-wake disorder and suggest-
ed to be immune-mediated, involving genetic and environ-
mental factors. The autoimmune process eventually leads to 
a loss of hypocretin neurons in the lateral hypothalamus. 
Epidemiological studies in several countries proved an in-
creased incidence of narcolepsy after H1N1 flu vaccination 
and infection. This survey in 30 sleep centers in Switzerland 
led to the identification of 9 H1N1-vaccinated children and 
adults as newly diagnosed narcolepsy. Clinical features in-
cluded the abrupt and severe onset of sleepiness, cataplexy 
and sleep fragmentation.  © 2016 S. Karger AG, Basel 
 Introduction 
 Narcolepsy-cataplexy (NC or narcolepsy type 1) is a 
chronic neurological sleep-wake disorder with a preva-
lence of 25–50 per 100,000 in western countries  [1] . The 
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ent purification process was detected in Pandemrix ® 
compared to Arepanrix ®  [12] .
 In Switzerland, 2 case reports were published in detail 
 [13] and overall 5 cases have been reported to the Swiss 
authorities until 2011  [14] . H1N1 vaccination coverage in 
Switzerland was approximately 17%.  Pandemrix ® was 
used in approximately 60% of all H1N1 vaccines. It was 
licensed for the use in adults (18–60 years) only  [15] . For 
children and adolescents, Focetria® and Celtura® have 
been licensed and used  [15] .
 There are no statistical data available on the incidence 
or prevalence of sporadic NC in Switzerland. The calcu-
lated number of new cases of narcolepsy in Switzerland 
assuming an incidence in the literature of 0.5/100,000 
would be of 40 per year.
 We aimed at assessing the frequency and characteris-
tics of post-H1N1 flu vaccination narcolepsy in 
 Switzerland.
 Methods 
 Since patients suspected for narcolepsy are usually referred to a 
specialized sleep center for final diagnosis by use of MSLT, HLA typ-
ing and hypocretin analysis  [16] , we based our survey on the Swiss 
sleep centers, accredited by the Swiss Society of Sleep Research, Sleep 
medicine and Chronobiology (www.swiss-sleep.ch). We contacted 
all sleep centers for ‘probable cases’ of NC in context of H1N1 vac-
cination since 2009. In case of a positive response, centers were asked 
for detailed data on their cases. Data were collected and analyzed 
using available medical documentation of the cases. Assessment in-
cluded demographic, clinical, MSLT, polysomnography (PSG) and 
laboratory data. Data were analyzed after anonymization.
 Results 
 Survey 
 Our survey had a high response rate; 29 out of 30 
(97%) sleep centers answered. Six centers reported pos-
sible H1N1-related cases of NC: Bern University Hospi-
tal, Department of Neurology (3), University Hospital 
Zurich, Department of Neurology (1), University Chil-
dren’s Hospital Zurich, Pediatric Sleep Disorders Center 
(1), University Hospitals of Geneva, Sleep Laboratory 
(1), CENAS Sleep Center, Geneva (1), University Hospi-
tal Lausanne, Sleep Center (2). For eight out of these nine 
patients additional details could be obtained.
 Patients 
 In all eight patients, EDS occurred as the first symp-
tom, followed by cataplexy and other NC symptoms a few 
days or weeks later ( table 1 ).
 Polysomnography 
 In seven out of eight patients, PSG was performed for 
diagnosis. In all patients, ‘sleep fragmentation,’ defined 
by poor sleep efficiency, was reported.
Table 1.  Clinical, MSLT, PSG and laboratory features of post-
H1N1 flu vaccination NC
n  Post H1N1 NC patients
 mean or % SD or range
Clinical data
Boys/men:girls/women, n 8 5:3
Age at diagnosis, years 8 20.4 9–39
Time between vaccination and
first symptoms, weeks 8 5.25 2–16
Weight gain* 8 50
NC symptoms
EDS at onset 8 100
EDS after 1 year 8 100
Cataplexy at onset 8 100
Cataplexy frequency at
onset, n/week 8 6.8 5.7
Cataplexy after 1 year 8 75
Cataplexy frequency after
1 year, n/week 8 0.75 2.5
Sleep paralysis at onset 7 85.7
Sleep paralyis after 1 year 7 28.5
Hypnagogic hallucinations
at onset 8 75
Hypnagogic hallucinations
after 1 year 8 37.5
Disturbed nocturnal sleep
at onset 8 75
Disturbed nocturnal sleep
after 1 year 8 75
MLST data
Mean sleep latency, min 8 2.00 1.56
SOREMPs (% of naps) 8 80.6
Polysomnography data
TST, min 7 413 47
Sleep efficiency 7 84 8
Laboratory data
HLA DQB1 0602 positive 8 100
CSF hypocretin < reference
values 6 100
 SOREMPs = Sleep-onset REM periods; TST = total sleep time.
‘Onset’ is defined as within the first 6 weeks after disease on-
set (first symptoms).
* Weight gain is defined as an increase in weight >5 kg with-
in 3 months after disease onset.
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 Family History 
 One patient reported a first-grade relative suffering 
from narcolepsy and 1 patient reported neurodermatitis. 
Besides this, no family history or co-occurrence of any 
other sleep or autoimmune disorders was reported.
 Vaccines 
 In seven out of eight patients, Pandemrix ® has been 
used. In 1 patient, Focetria ® has been used.
 Diagnostic Latency and Date of Diagnosis 
 Mean diagnostic latency was 13.4 months; six out of 
eight patients were diagnosed in 2010, 2 patients in 
2013.
 Discussion 
 The main aims of this study were the evaluation of the 
frequency and clinical characteristics of NC following 
H1N1 flu vaccine administration in Switzerland. 
 Frequency 
 The vaccination coverage was approximately 17% and 
thus comparable to other central European countries. On 
the basis of the calculated number of 40 newly diagnosed 
cases of narcolepsy per year (including post-H1N1 NC), 
the notified total number of (8) 9 post-H1N1 vaccination 
cases is within the normal range and primarily does not 
indicate an elevated risk. An increase of narcolepy diag-
noses was mainly found in children and adolescents 
[17, 18], in Scandinavian countries in particular [19]. In 
 Switzerland, Pandemrix® has not been applied in chil-
dren and adolescents. This likely had an impact on the 
(probably) normal number of narcolepsy cases occurring. 
Additional epidemiological data, incidence data most 
 notably, are needed for Switzerland.
 Clinical Characteristics 
 Some recent studies have reported on specific fea-
tures in post-H1N1 vaccination narcolepsy. Dauvilliers 
et al.  [9] described an abrupt and severe onset of EDS 
and cataplexy and Pizza et al.  [20] found higher num-
bers of post H1N1 NC patients with disturbed sleep. 
Our results are in line with these findings. In addition, 
we found high numbers of sleep paralysis and hallucina-
tions immediately being present at disease onset. Our 
data support the description of post-H1N1 vaccination 
NC showing a ‘full-blown’ spectrum from the onset of 
disease.
 Clinical Course – Evolution 
 There are limited data on the spontaneous course of 
post-H1N1 vaccination narcolepsy. Almost all of our pa-
tients (7/8) received symptomatic pharmacological treat-
ment. Hence, improvement of EDS, as described by a 
majority of the patients can be explained by the treat-
ment. Only 3 patients were treated with specific drugs 
against cataplexy, but almost all patients described an 
improvement of this symptom in the early course. In a 
majority of patients, sleep fragmentation, sleep-related 
hallucinations and sleep paralysis also became less, later 
on.
 A remarkable, spontaneous improvement of cataplexy 
has been described in sporadic NC  [21] , and is therefore 
not an exclusive feature of post H1N1 NC.
 Limitations of this study include the retrospective 
study design, small sample size and lack of epidemiologi-
cal data.
 The temporal association of H1N1 flu vaccination and 
narcolepsy and suggested specific clinical features in 
post-H1N1 vaccination narcolepsy strengthen the hy-
pothesis of an autoimmune process as a driving force in 
the pathogenesis of narcolepsy.
 Long-term studies from countries with higher H1N1 
vaccination rates are needed to better evaluate the clinical 
characteristics and course of post H1N1 NC.
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